Unable to Reach Licensing Deal, Rosetta Genomics Will Not Receive $1.25M Payment | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Unable to reach a licensing deal with a lender, Rosetta Genomics will not receive a $1.25 million payment, the company disclosed in a document filed with the US Securities and Exchange Commission today.

Rosetta and the unnamed lender had agreed to negotiate for the licensing deal as part of a $1.75 million private placement raise that Rosetta announced in late January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.